Martin Pflügler

Title: Martin Pflügler: Innovator in Anti-FLT Antigen Binding Proteins

Introduction

Martin Pflügler is a notable inventor based in Tübingen, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of anti-FLT antigen binding proteins. His work focuses on improving the efficacy of treatments for diseases such as leukemia.

Latest Patents

Martin Pflügler holds a patent for "Anti-FLT Antigen Binding Proteins." This invention provides novel human fins related to tyrosine kinase 3 (FLT) antigen binding proteins, including antibodies with enhanced FLT binding affinity and anti-tumor activity. The FLT antibodies were generated through mutation of a parent FLT antibody and were rigorously tested in both in vitro binding assays and in vivo mouse tumor models, as well as in human patient tumor samples. The antibodies can be presented as monospecific constructs or in a bispecific FLT×CD antibody format, demonstrating excellent target affinity and tumor cell killing capabilities. Additionally, the invention encompasses methods for producing these antigen binding proteins, along with nucleic acids encoding them, vectors for their expression, and host cells. The invention also outlines methods for treating or diagnosing diseases such as leukemia using the FLT antigen binding proteins.

Career Highlights

Throughout his career, Martin Pflügler has worked with esteemed institutions, including the Deutsches Krebsforschungszentrum (German Cancer Research Center) and Eberhard Karls University of Tübingen. His research has significantly advanced the understanding and treatment of cancer-related diseases.

Collaborations

Martin Pflügler has collaborated with notable professionals in his field, including Gundram Jung. Their joint efforts have contributed to the development of innovative solutions in cancer treatment.

Conclusion

Martin Pflügler's work in the development of anti-FLT antigen binding proteins showcases his dedication to advancing medical science and improving treatment options for patients with leukemia. His contributions are invaluable to the field of biotechnology and cancer research.